Skip to content
All articles

ER Stress Explained: Why TUDCA Is Studied as a Chaperone

A fluorescence micrograph of human cells glowing blue-green on a dark ground, with a search bar reading "What is ER stress?"
Table of contents
  1. What to know
  2. What Does Endoplasmic Reticulum Stress Mean?
  3. What Is the Unfolded Protein Response?
  4. What Is a Chemical Chaperone?
  5. Why Is TUDCA Studied as a Chemical Chaperone?
  6. Does TUDCA Reduce ER Stress in People?
  7. What Happened When Chaperones Were Tested as Medicines?
  8. How Does TUDCA Work in the Body?
  9. In Summary: ER Stress and TUDCA
  10. Frequently Asked Questions
  11. References

ER stress is what happens when a cell's protein-folding workshop, the endoplasmic reticulum, receives more unfinished proteins than it can fold. TUDCA is studied as a "chemical chaperone" because in cells and mice it eased this stress, but in the one placebo-controlled trial that measured stress markers in people, they did not change.


What to know

  • The endoplasmic reticulum (ER) is the part of a cell where many proteins are folded into their working shapes.
  • When misfolded proteins build up, the cell switches on the unfolded protein response, and lasting stress can kill the cell.
  • Chemical chaperones are small molecules that help stabilize protein folding; TUDCA and 4-phenylbutyrate are two examples.
  • In obese mice, both eased ER stress and improved blood sugar control.
  • In a four-week placebo-controlled trial in people, ER stress markers in muscle and fat did not change on TUDCA.

Read about how TUDCA works and you will soon meet two phrases: ER stress and chemical chaperone. They come from cell biology, and they are often presented as if they explained everything TUDCA does in the body. The research behind them is real, but almost all of it was done in cells and animals.

This guide explains what ER stress is, what a chemical chaperone does, why researchers study TUDCA as one, and what the studies in people have and haven't found. It is a science explainer, so it sticks to what was measured and where.

What Does Endoplasmic Reticulum Stress Mean?

Endoplasmic reticulum stress, or ER stress, means the cell's protein-folding system is overloaded. The endoplasmic reticulum is a network of membranes inside the cell where many proteins, including those that are secreted or sit on the cell's surface, are folded into their working shapes [1]. When proteins fold incorrectly and build up there, the cell senses the problem [2].

A useful way to picture it is a busy workshop. As long as the work arrives at a manageable pace, finished products leave in good shape. When too much arrives, or something disrupts the process, half-finished items pile up and the workshop has to slow down and catch up.

What Is the Unfolded Protein Response?

The unfolded protein response is the cell's way of dealing with that pile-up. It increases the cell's folding capacity by making more chaperones, and makes more of the enzymes that clear misfolded proteins [2, 1]. If those steps restore balance, the cell carries on. If the stress isn't resolved, the same response can trigger the cell's own death program [1].

That switch from repair to cell death is why ER stress interests researchers. It has been studied in conditions where cells are under sustained strain, including obesity and diabetes, where it was linked in animal studies to how the liver and other tissues respond to insulin [3, 4].

What are the markers for ER stress?

In research, ER stress is measured through molecules that rise when the unfolded protein response switches on, such as GRP78, a chaperone protein in the ER [5]. In studies, they are measured in tissue samples, such as muscle and fat biopsies, rather than in a routine blood test [6].

What Is a Chemical Chaperone?

A chemical chaperone is a small molecule that helps stabilize proteins in their correct shape. Researchers describe compounds such as 4-phenylbutyrate as low molecular weight molecules known to stabilize protein conformation, and TUDCA as another compound that can modulate ER function [3]. A review of the field describes using chemical chaperones to restore ER function as a strategy under study [4].

What are the two types of chaperones?

Cells make their own chaperones, which are proteins that help other proteins fold; GRP78 (also called BiP) in the ER is one of them [2, 5]. Chemical chaperones are different: they are small molecules, some made in the body and some given as drugs, that support folding without being proteins themselves [3, 4].

Why Is TUDCA Studied as a Chemical Chaperone?

TUDCA is studied as a chemical chaperone because it eased ER stress in experiments in mice. In obese mice lacking the hormone leptin, both TUDCA and 4-phenylbutyrate reduced ER stress, lowered blood sugar and insulin, reduced fat in the liver and brought liver enzymes back toward normal [3]. The researchers called both "orally active chemical chaperones".

Cell studies have added detail. In mouse intestinal cells stressed with a drug that blocks protein folding, TUDCA strongly inhibited the rise in GRP78 [5]. When the researchers split the molecule into its parts, taurine alone did not have this effect, and unconjugated UDCA was about ten times more effective than TUDCA in that system [5]. So in this experiment, the chaperone effect belonged to the bile acid part of the molecule.

A review of TUDCA's uses outside the liver describes many more laboratory studies in models of brain, eye and metabolic disease [7]. Those findings explain why the idea is attractive, but they are cell and animal results.

Does TUDCA Reduce ER Stress in People?

In the one placebo-controlled trial that measured ER stress markers in people, they did not change; a small uncontrolled study reported lower markers in the colon. In the trial, 20 adults with obesity took 1,750 mg of TUDCA a day or placebo for four weeks, and the markers in their muscle and fat tissue did not change [6]. In the same trial, insulin sensitivity of the liver and muscles rose about 30% on TUDCA and not on placebo [6], so whatever produced that change, it wasn't visible as lower ER stress in those tissues (no liver tissue was sampled).

An open-label study of 14 people with ulcerative colitis, published as a preprint, reported lower ER stress markers in samples from the colon lining after six weeks [8]. It had no comparison group and has not yet been peer reviewed. Together, these two studies are a starting point rather than an answer.

Recommended to you

Post-Gallbladder Bile & Liver Support

  • Restore Bile Fluidity
  • Improve Fat Breakdown
  • Support Liver Cells

What Happened When Chaperones Were Tested as Medicines?

The idea of chemical chaperones has been tested in people with ALS, a disease of the nerves that control movement. A US prescription drug combined the two chaperones from the mouse studies, sodium phenylbutyrate and taurursodiol (TUDCA), and was approved in 2022 [9]. After a larger trial did not meet its goals, the company took it off the market in 2024, and the FDA formally withdrew its approval in 2025 [10, 11]. A separate large trial of TUDCA alone in ALS also fell short [12].

Those results don't settle the question for other conditions, but they show how hard it is to turn results in cells and animals into a benefit in people.

How Does TUDCA Work in the Body?

The best-documented thing TUDCA does in people is simpler than ER stress. Taken by mouth, it is absorbed and joins the bile acids your body recycles, and in people with a liver condition it raised the share of UDCA and its conjugates in bile to about a third or more [13]. In people with gallstones, bile became less saturated with cholesterol as the dose rose [14].

That bile-based role is why TUDCA is used as a supplement to support healthy bile flow and fat digestion. Dr.Primal's TUDCA is made for life after gallbladder removal and taken with meals, when your body calls on bile the most. Our guide to what TUDCA is explains how it is made in the body and what it is used for.

In Summary: ER Stress and TUDCA

ER stress is the strain on a cell when misfolded proteins pile up in its folding workshop, and chemical chaperones are small molecules that help ease it. TUDCA earned its place on that list from results in mice and cells, but in the one placebo-controlled trial that measured ER stress markers in people, they did not change, and chaperone drugs have not yet succeeded in ALS.

For readers without a gallbladder, TUDCA's role in bile is the part that has been measured in people, though not yet in people without a gallbladder. If you are working out what is behind your symptoms after meals, our digestion quiz is a quick way to put your symptoms and habits in order.

For the studies themselves, see our evidence reviews on TUDCA, bile acids and gallbladder removal. Five neutral reviews of the studies in people, with methods, grades and sources.

Frequently Asked Questions

What causes ER stress?

ER stress happens whenever misfolded proteins build up faster than the cell can handle them [2]. In the lab, researchers trigger it with drugs that block protein folding [5], and in animal studies it has been linked to obesity, where it was found in the liver and fat tissue of obese mice [3].

Is TUDCA an ER stress inhibitor?

In cells and mice, TUDCA reduced ER stress, which is why it is used as a research tool [3, 5]. In people, the one placebo-controlled trial that measured ER stress markers found no change in four weeks [6], so it hasn't been shown to work that way in humans.

How do you know if TUDCA is working?

There is no test you can use for ER stress, so people judge TUDCA by whatever they are taking it for, such as how meals feel. Our guide to how long TUDCA takes to work covers what the studies' timelines show.

Is TUDCA hard on your liver?

In trials in people with liver conditions, liver enzymes generally fell on TUDCA rather than rose [15]. Our guide to TUDCA for liver health covers the safety data.

References

  1. Walter P, Ron D. The unfolded protein response: from stress pathway to homeostatic regulation. Science. 2011;334(6059):1081-1086. PubMed
  2. Alberts B, Johnson A, Lewis J, et al. The endoplasmic reticulum. In: Molecular Biology of the Cell. 4th ed. Garland Science; 2002. NCBI Bookshelf NBK26841. NCBI Bookshelf
  3. Ozcan U, Yilmaz E, Ozcan L, et al. Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science. 2006;313(5790):1137-1140. PubMed
  4. Engin F, Hotamisligil GS. Restoring endoplasmic reticulum function by chemical chaperones: an emerging therapeutic approach for metabolic diseases. Diabetes Obes Metab. 2010;12 Suppl 2:108-115. PubMed
  5. Berger E, Haller D. Structure-function analysis of the tertiary bile acid TUDCA for the resolution of endoplasmic reticulum stress in intestinal epithelial cells. Biochem Biophys Res Commun. 2011;409(4):610-615. PubMed
  6. Kars M, Yang L, Gregor MF, et al. Tauroursodeoxycholic Acid may improve liver and muscle but not adipose tissue insulin sensitivity in obese men and women. Diabetes. 2010;59(8):1899-1905. PubMed
  7. Vang S, Longley K, Steer CJ, Low WC. The unexpected uses of urso- and tauroursodeoxycholic acid in the treatment of non-liver diseases. Glob Adv Health Med. 2014;3(3):58-69. DOI
  8. Lamm V, Huang K, Deng R, et al. Tauroursodeoxycholic Acid (TUDCA) Reduces ER Stress and Lessens Disease Activity in Ulcerative Colitis. medRxiv. 2025. Preprint posted April 4, 2025. doi:10.1101/2025.04.02.25322684. PubMed
  9. Amylyx Pharmaceuticals. RELYVRIO (sodium phenylbutyrate and taurursodiol) for oral suspension: prescribing information. Revised September 2022. Drugs@FDA. FDA
  10. Amylyx Pharmaceuticals. Amylyx Pharmaceuticals announces formal intention to remove RELYVRIO/ALBRIOZA from the market. Press release, April 4, 2024 (Form 8-K, exhibit 99.1). SEC
  11. Food and Drug Administration. Amylyx Pharmaceuticals, Inc.; withdrawal of approval of new drug application for RELYVRIO (sodium phenylbutyrate and taurursodiol) for suspension, 3 gram/packet and 1 gram/packet. Fed Regist. 2025;90(166):42251. Federal Register
  12. Meglio M. Tauroursodeoxycholic acid falls short in phase 3 study of amyotrophic lateral sclerosis. NeurologyLive. April 4, 2024. NeurologyLive
  13. Setchell KD, Rodrigues CM, Podda M, Crosignani A. Metabolism of orally administered tauroursodeoxycholic acid in patients with primary biliary cirrhosis. Gut. 1996;38(3):439-446. PubMed
  14. Muraca M, Vilei MT, Cianci V, Liu XT, Garotta F. Effect of tauroursodeoxycholic acid on biliary lipid composition. A dose-response study. Int J Clin Pharmacol Ther. 1995;33(7):391-393. PubMed
  15. Crosignani A, Budillon G, Cimino L, et al. Tauroursodeoxycholic acid for the treatment of HCV-related chronic hepatitis: a multicenter placebo-controlled study. Hepatogastroenterology. 1998;45(23):1624-1629. PubMed

This article is for general education and is not a substitute for advice from your doctor. TUDCA is sold as a dietary supplement. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

Read next

Welcome offer